SAN DIEGO, Calif. and ZUG, Switzerland, Nov. 10, 2023 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that following a re-examination procedure, the Company has received a positive opinion from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on…Read More
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI adagrasib as a Targeted Treatment Option for Patients with Advanced NonSmall Cell Lung Cancer NSCLC with a KRASG12C Mutation Following a ReExamination Procedure
